《怪奇物语》：雄激素受体在肿瘤学中除前列腺癌以外的新角色和新机遇
Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
机构信息
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
出版信息
Endocrinology. 2023 Apr 17;164(6). doi: 10.1210/endocr/bqad071.
The androgen receptor (AR) is one of the oldest therapeutic targets in oncology and continues to dominate the treatment landscape for advanced prostate cancer, where nearly all treatment regimens include some form of AR modulation. In this regard, AR remains the central driver of prostate cancer cell biology. Emerging preclinical and clinical data implicate key roles for AR in additional cancer types, thereby expanding the importance of this drug target beyond prostate cancer. In this mini-review, new roles for AR in other cancer types are discussed as well as their potential for treatment with AR-targeted agents. Our understanding of these additional functions for AR in oncology expand this receptor's potential as a therapeutic target and will help guide the development of new treatment approaches.
雄激素受体（AR）是肿瘤学中最古老的治疗靶点之一，在晚期前列腺癌的治疗中仍然占据主导地位，几乎所有的治疗方案都包括某种形式的 AR 调节。在这方面，AR 仍然是前列腺癌细胞生物学的核心驱动因素。新出现的临床前和临床数据表明 AR 在其他癌症类型中起关键作用，从而使该药物靶点的重要性超出了前列腺癌的范围。在这篇迷你综述中，讨论了 AR 在其他癌症类型中的新作用及其用 AR 靶向药物治疗的潜力。我们对 AR 在肿瘤学中的这些额外功能的理解扩展了该受体作为治疗靶点的潜力，并将有助于指导新的治疗方法的开发。
Zotero 插件